Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in ÎçÒ¹¸£Àû1000¼¯ºÏ) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Physics
The 50-year quest to create a quantum spin liquid may finally be over
Features
Technology
Backlash builds over NHS plan to hide source code from AI hacking risk
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
Hantavirus: Where has the deadly cruise ship outbreak come from?
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
Woman in cancer remission without treatment in highly unusual case
News
Popular articles
Trending New Scientist articles
1
Man destined to get Alzheimer’s saved by accidental heat therapy
2
A lost ancient script reveals how writing as we know it really began
3
Woman in cancer remission without treatment in highly unusual case
4
Hantavirus: Where has the deadly cruise ship outbreak come from?
5
We have figured out a new way to send messages into the past
6
Honey has been used as medicine for centuries – does it really work?
7
Prebiotic chewing gum could be helpful for gum disease
8
Thought-provoking photographs capture what it feels like to have ADHD
9
Backlash builds over NHS plan to hide source code from AI hacking risk
10
Your oral microbiome could affect your weight, liver and diabetes risk
